Steven H. Belle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven H. Belle has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Wendy C. King
Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, USA
7 shared publications - John Michael Jakicic
University of Kansas Medical Center, Kansas City, KS
5 shared publications - Abdus S. Wahed
Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA
4 shared publications Abdus S. Wahed
2 shared publicationsAnita P. Courcoulas
University of Pittsburgh Medical Center
2 shared publications- Bruce M. Wolfe
Oregon Health and Science University
2 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (9) , 1867-1875
The Physiology Of the WEight Reduced State (POWERS) study: overview and study design
Obesity is a multifactorial disease caused by physiological and environmental factors. Adults who have obesity are at increased risk for several additional chronic and infectious diseases, resulting in reduced life expectancy, compared to those with lower body mass indices. Weight loss (WL) has several clinical benefits to reducing these risks. However, among those who intentionally lose weight, it is common for some, or all, of the lost weight to be regained. There is evidence that changes affecting energy intake or expenditure, including metabolic adaptations in the weight-reduced state, work against maintaining WL. The Physiology Of the WEight Reduced State consortium (POWERS) designed a study to describe behavioral and metabolic adaptations to the weight reduced state and to examine their contributions to weight variability following WL. This is accomplished by quantifying physiological, psychosocial, behavioral and other factors before and after a behavioral intervention that induces WL. The primary goal of POWERS is to identify factors that explain the variability in weight change following intentional weight loss. This multi-center project includes a POWERS-designed WL intervention implemented at two clinical centers for 205 enrolled participants. Those losing at least 7% of their pre-intervention weight and attaining weight stability are followed in a 1-year observational phase that includes sequential physiological and behavioral phenotyping. It is anticipated that 70% of those enrolled in the WL program will enter the observational phase of the study and that 100 will complete the study. The primary outcome is weight change during the observational period with primary independent variables measuring energy intake and energy expenditure. Detailed endophenotypes of energy intake and energy expenditure are assessed using a combination of biospecimens, neuroimaging, objective measures (e.g., doubly labeled water, calorimetry, accelerometry, polysomnography), self-report questionnaires, and interviews to address their contributions to weight change variability up to 1 year following WL.
- 12 December 2025
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (9) , 1867-1875
Open AccessThe Physiology Of the WEight Reduced State (POWERS) study: overview and study design
Obesity is a multifactorial disease caused by physiological and environmental factors. Adults who have obesity are at increased risk for several additional chronic and infectious diseases, resulting in reduced life expectancy, compared to those with lower body mass indices. Weight loss (WL) has several clinical benefits to reducing these risks. However, among those who intentionally lose weight, it is common for some, or all, of the lost weight to be regained. There is evidence that changes affecting energy intake or expenditure, including metabolic adaptations in the weight-reduced state, work against maintaining WL. The Physiology Of the WEight Reduced State consortium (POWERS) designed a study to describe behavioral and metabolic adaptations to the weight reduced state and to examine their contributions to weight variability following WL. This is accomplished by quantifying physiological, psychosocial, behavioral and other factors before and after a behavioral intervention that induces WL. The primary goal of POWERS is to identify factors that explain the variability in weight change following intentional weight loss. This multi-center project includes a POWERS-designed WL intervention implemented at two clinical centers for 205 enrolled participants. Those losing at least 7% of their pre-intervention weight and attaining weight stability are followed in a 1-year observational phase that includes sequential physiological and behavioral phenotyping. It is anticipated that 70% of those enrolled in the WL program will enter the observational phase of the study and that 100 will complete the study. The primary outcome is weight change during the observational period with primary independent variables measuring energy intake and energy expenditure. Detailed endophenotypes of energy intake and energy expenditure are assessed using a combination of biospecimens, neuroimaging, objective measures (e.g., doubly labeled water, calorimetry, accelerometry, polysomnography), self-report questionnaires, and interviews to address their contributions to weight change variability up to 1 year following WL.
- Open Access
- 13 November 2025
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (1) , 1-2
Introduction to the special issue describing the Physiology Of the WEight Reduced State (POWERS) Study
- 13 November 2025
- Published by Springer Nature in International Journal of Obesity
- Vol. 50 (1) , 1-2
Open AccessIntroduction to the special issue describing the Physiology Of the WEight Reduced State (POWERS) Study
- 15 May 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (6)
Safety and yield of percutaneous liver biopsy in adults and children with chronic hepatitis B: Results from a prospective, multicenter study
Background: Prospective data regarding the safety and yield of liver biopsy in both adults and children with chronic hepatitis B are limited. The aim of this study is to report safety, yield, and complication rates among adults and children with chronic hepatitis B undergoing percutaneous liver biopsy. Methods: Data on the indication for procedural characteristics and complication rate for liver biopsies performed as part of the Hepatitis B Research Network were prospectively recorded on a study case report form and analyzed in aggregate. Results: Among 2506 adult and pediatric subjects enrolled in the Hepatitis B Research Network between 2011 and 2018, 465 (19%) underwent 491 liver biopsies for clinical or research reasons. Adequate liver tissue was obtained in 98% of the procedures. In total, there were 32 complications reported for 24 biopsies: 23 biopsies with 30 complications in adults and 1 biopsy with 2 complications in children. Pain (n=19) and vasovagal reaction (n=6) were the most common complications. There were 7 serious adverse events, including an arterioportal venous fistula, a pneumothorax, 4 cases of bleeding, and severe pain with no associated condition. There were no deaths. Conclusions: These data demonstrate that percutaneous liver biopsy is associated with a high yield of tissue (98%) and a rate of serious complications of 1.4% in both children and adults with chronic HBV. These results support the focused use of liver biopsy in the evaluation of novel treatments in development for chronic hepatitis B.
- 15 May 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (6)
Safety and yield of percutaneous liver biopsy in adults and children with chronic hepatitis B: Results from a prospective, multicenter study
Background: Prospective data regarding the safety and yield of liver biopsy in both adults and children with chronic hepatitis B are limited. The aim of this study is to report safety, yield, and complication rates among adults and children with chronic hepatitis B undergoing percutaneous liver biopsy. Methods: Data on the indication for procedural characteristics and complication rate for liver biopsies performed as part of the Hepatitis B Research Network were prospectively recorded on a study case report form and analyzed in aggregate. Results: Among 2506 adult and pediatric subjects enrolled in the Hepatitis B Research Network between 2011 and 2018, 465 (19%) underwent 491 liver biopsies for clinical or research reasons. Adequate liver tissue was obtained in 98% of the procedures. In total, there were 32 complications reported for 24 biopsies: 23 biopsies with 30 complications in adults and 1 biopsy with 2 complications in children. Pain (n=19) and vasovagal reaction (n=6) were the most common complications. There were 7 serious adverse events, including an arterioportal venous fistula, a pneumothorax, 4 cases of bleeding, and severe pain with no associated condition. There were no deaths. Conclusions: These data demonstrate that percutaneous liver biopsy is associated with a high yield of tissue (98%) and a rate of serious complications of 1.4% in both children and adults with chronic HBV. These results support the focused use of liver biopsy in the evaluation of novel treatments in development for chronic hepatitis B.
- Open Access
- 13 January 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 118 (7) , 1226-1236
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial
INTRODUCTION: Withdrawal of nucleos(t)ide analog therapy is increasingly being evaluated in chronic hepatitis B infection as a strategy to induce hepatitis B surface antigen (HBsAg) loss. The Hepatitis B Research Network Immune-Active Trial evaluated treatment with tenofovir (TDF) for 4 years ± an initial 6 months of peginterferon-α (PegIFN) (NCT01369212) after which treatment was withdrawn. METHODS: Eligible participants (hepatitis B e antigen [HBeAg]−/anti-HBe+, hepatitis B virus [HBV] DNA 5× upper limit of normal) after TDF withdrawal occurred in 36 (37.1%) participants and occurred more frequently and earlier in those HBeAg− compared with HBeAg+ at treatment initiation. ALT flares were associated with older age and higher HBV DNA pretreatment and at the visit before the flare. ALT flares were not significantly associated with HBsAg decline or loss but were associated with immune active disease at 1 year (70.6% vs 11.9%, P < 0.0001) and 2 years (66.7% vs 25.9%, P = 0.03) postwithdrawal. Treatment reinitiation was required in 13 (13.4%) participants, and 13 others remained in a sustained inactive carrier state by the end of the study follow-up. No criteria reliably predicted safe treatment withdrawal. DISCUSSION: Results from this trial do not support TDF withdrawal as a therapeutic strategy. HBsAg loss was infrequent within 2 years of stopping long-term TDF. If withdrawal is considered, HBV DNA should be carefully monitored with reinitiation of therapy if levels rise above 4 log 10 IU/mL to reduce the risk of ALT flares, as they were not associated with subsequent HBsAg decline or loss.
- 13 January 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 118 (7) , 1226-1236
Open AccessWithdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial
INTRODUCTION: Withdrawal of nucleos(t)ide analog therapy is increasingly being evaluated in chronic hepatitis B infection as a strategy to induce hepatitis B surface antigen (HBsAg) loss. The Hepatitis B Research Network Immune-Active Trial evaluated treatment with tenofovir (TDF) for 4 years ± an initial 6 months of peginterferon-α (PegIFN) (NCT01369212) after which treatment was withdrawn. METHODS: Eligible participants (hepatitis B e antigen [HBeAg]−/anti-HBe+, hepatitis B virus [HBV] DNA 5× upper limit of normal) after TDF withdrawal occurred in 36 (37.1%) participants and occurred more frequently and earlier in those HBeAg− compared with HBeAg+ at treatment initiation. ALT flares were associated with older age and higher HBV DNA pretreatment and at the visit before the flare. ALT flares were not significantly associated with HBsAg decline or loss but were associated with immune active disease at 1 year (70.6% vs 11.9%, P < 0.0001) and 2 years (66.7% vs 25.9%, P = 0.03) postwithdrawal. Treatment reinitiation was required in 13 (13.4%) participants, and 13 others remained in a sustained inactive carrier state by the end of the study follow-up. No criteria reliably predicted safe treatment withdrawal. DISCUSSION: Results from this trial do not support TDF withdrawal as a therapeutic strategy. HBsAg loss was infrequent within 2 years of stopping long-term TDF. If withdrawal is considered, HBV DNA should be carefully monitored with reinitiation of therapy if levels rise above 4 log 10 IU/mL to reduce the risk of ALT flares, as they were not associated with subsequent HBsAg decline or loss.
- Open Access
- 19 September 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (9) , e0221683
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease and may be a treatment for NASH due to its antioxidant properties. We aimed to assess the safety and efficacy of higher than customary doses of silymarin in non-cirrhotic patients with NASH. This exploratory randomized double-blind placebo controlled multicenter Phase II trial tested a proprietary standardized silymarin preparation (Legalon®, Rottapharm|Madaus, Mylan) and was conducted at 5 medical centers in the United States. Eligible adult patients had liver biopsy within 12 months showing NASH without cirrhosis with NAFLD Activity Score (NAS) ≥4 per site pathologist’s assessment. Participants were randomized to Legalon® 420 mg, 700 mg, or placebo t.i.d. for 48 weeks. The primary endpoint was histological improvement ≥2 points in NAS. Of 116 patients screened, 78 were randomized. There were no significant differences in adverse events among the treatment groups. After 48–50 weeks, 4/27 (15%) in the 700 mg dose, 5/26 (19%) participants randomized to 420 mg, and 3/25 (12%) of placebo recipients reached the primary endpoint (p = 0.79) among all randomized participants, indicating no benefit from silymarin in the intention to treat analysis Review by a central pathologist demonstrated that a substantial number of participants (49, 63%) did not meet histological entry criteria and that fibrosis stage improved most in the placebo treated group, although not significantly different from other groups. Silymarin (Legalon®) at the higher than customary doses tested in this study is safe and well tolerated. The effect of silymarin in patients with NASH remains inconclusive due to the substantial number of patients who entered the study but did not meet entry histological criteria, the lack of a statistically significant improvement in NAS of silymarin treated patients, and the unanticipated effect of placebo on fibrosis indicate the need for additional clinical trials. Trial Registration: clinicaltrials.gov, Identifier: NCT00680407.
- 19 September 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (9) , e0221683
Open AccessSilymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease and may be a treatment for NASH due to its antioxidant properties. We aimed to assess the safety and efficacy of higher than customary doses of silymarin in non-cirrhotic patients with NASH. This exploratory randomized double-blind placebo controlled multicenter Phase II trial tested a proprietary standardized silymarin preparation (Legalon®, Rottapharm|Madaus, Mylan) and was conducted at 5 medical centers in the United States. Eligible adult patients had liver biopsy within 12 months showing NASH without cirrhosis with NAFLD Activity Score (NAS) ≥4 per site pathologist’s assessment. Participants were randomized to Legalon® 420 mg, 700 mg, or placebo t.i.d. for 48 weeks. The primary endpoint was histological improvement ≥2 points in NAS. Of 116 patients screened, 78 were randomized. There were no significant differences in adverse events among the treatment groups. After 48–50 weeks, 4/27 (15%) in the 700 mg dose, 5/26 (19%) participants randomized to 420 mg, and 3/25 (12%) of placebo recipients reached the primary endpoint (p = 0.79) among all randomized participants, indicating no benefit from silymarin in the intention to treat analysis Review by a central pathologist demonstrated that a substantial number of participants (49, 63%) did not meet histological entry criteria and that fibrosis stage improved most in the placebo treated group, although not significantly different from other groups. Silymarin (Legalon®) at the higher than customary doses tested in this study is safe and well tolerated. The effect of silymarin in patients with NASH remains inconclusive due to the substantial number of patients who entered the study but did not meet entry histological criteria, the lack of a statistically significant improvement in NAS of silymarin treated patients, and the unanticipated effect of placebo on fibrosis indicate the need for additional clinical trials. Trial Registration: clinicaltrials.gov, Identifier: NCT00680407.
- 1 February 2019
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 15 (2) , 269-278
A longitudinal examination of suicide-related thoughts and behaviors among bariatric surgery patients
- 1 February 2019
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 15 (2) , 269-278
A longitudinal examination of suicide-related thoughts and behaviors among bariatric surgery patients
- Open Access
- 27 June 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1-6
Specifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC)
Sickle cell disease (SCD) is an inherited blood disorder that results in a lifetime of anemia, severe pain, and end-organ damage that can lead to premature mortality. While the SCD field has made major medical advances, much needs to be done to improve the quality of care for people with SCD. This study capitalizes on the Sickle Cell Disease Implementation Consortium (SCDIC), a consortium of eight academic sites aiming to test implementation strategies that could lead to more accelerated application of the NHLBI guidelines for treating SCD. This report documents the process to support the consortium by specifying the interventions being developed. This study consists of three steps. The Principal Investigator of each site and two site representatives who are knowledgeable of the intervention (e.g., study coordinator or the person delivering the intervention) will answer an online survey aiming to capture components of the interventions. This survey will be completed by the site representatives three times during the study: during the development of the interventions, after one year of the interventions being implemented, and at the end of this study (after 2 years). A site visit and semi-structured interview (Step 2) in the first year of the process will capture the context of the sites. Step 3 comprises of the development of a framework with the details of the multi-component SCDIC interventions at the sites. The outcome of this study, a framework of the SCDIC, will enable accurate replication and extension of published research, facilitating the translation of SCD studies to diverse populations and settings and allowing for theory testing of the effects of the intervention components across studies in different contexts and for different populations. ClinicalTrial.Gov (# NCT03380351 ). Registered December 21, 2017.
- 27 June 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1-6
Open AccessSpecifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC)
Sickle cell disease (SCD) is an inherited blood disorder that results in a lifetime of anemia, severe pain, and end-organ damage that can lead to premature mortality. While the SCD field has made major medical advances, much needs to be done to improve the quality of care for people with SCD. This study capitalizes on the Sickle Cell Disease Implementation Consortium (SCDIC), a consortium of eight academic sites aiming to test implementation strategies that could lead to more accelerated application of the NHLBI guidelines for treating SCD. This report documents the process to support the consortium by specifying the interventions being developed. This study consists of three steps. The Principal Investigator of each site and two site representatives who are knowledgeable of the intervention (e.g., study coordinator or the person delivering the intervention) will answer an online survey aiming to capture components of the interventions. This survey will be completed by the site representatives three times during the study: during the development of the interventions, after one year of the interventions being implemented, and at the end of this study (after 2 years). A site visit and semi-structured interview (Step 2) in the first year of the process will capture the context of the sites. Step 3 comprises of the development of a framework with the details of the multi-component SCDIC interventions at the sites. The outcome of this study, a framework of the SCDIC, will enable accurate replication and extension of published research, facilitating the translation of SCD studies to diverse populations and settings and allowing for theory testing of the effects of the intervention components across studies in different contexts and for different populations. ClinicalTrial.Gov (# NCT03380351 ). Registered December 21, 2017.
- 1 January 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (1) , 27-28
Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial
- 1 January 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (1) , 27-28
Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial
- Top Cited PapersOpen Access
- 20 September 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 316 (11) , 1161-1171
Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss
Overweight and obesity have high prevalence1 and are associated with numerous health conditions.2 Interventions emphasizing both diet and physical activity are effective for weight loss, resulting in 6-month weight loss of 8% to 10% of initial weight.3 However, challenges remain to sustaining weight loss long-term.3
- 20 September 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 316 (11) , 1161-1171
Top Cited PapersOpen AccessEffect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss
Overweight and obesity have high prevalence1 and are associated with numerous health conditions.2 Interventions emphasizing both diet and physical activity are effective for weight loss, resulting in 6-month weight loss of 8% to 10% of initial weight.3 However, challenges remain to sustaining weight loss long-term.3
- 1 March 2016
- Published by Elsevier in Preventive Medicine
- Vol. 84, 12-18
Objectively-measured sedentary time and cardiometabolic health in adults with severe obesity
- 1 March 2016
- Published by Elsevier in Preventive Medicine
- Vol. 84, 12-18
Objectively-measured sedentary time and cardiometabolic health in adults with severe obesity